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Introduction
Over the past three decades, archived HIV samples have 
allowed commercial and academic researchers to develop and 
evaluate multiple new HIV assays and HIV diagnostic strate-
gies, including new approaches to measure and monitor HIV 
prevalence and incidence1,2. This has allowed us to achieve 
improved sensitivity and specificity of assays with reduced 
time to detect infection following HIV acquisition3–8, attain an 
increased range of incidence and prognostic biomarkers9–11, 
advance techniques for identification of diverse HIV geno-
types and recombinant viruses as well as prediction of drug 
resistance12–18, and automate and increase throughput of diag-
nostic platforms19,20. Through these enhanced strategies we have 
not only broadened the range of potential specimen types 
that can be used in diagnostic and incidence testing21–23, but we 
have also increased the settings in which testing occurs24,25 and 
improved estimates of infection timing26,27.
Yet despite these advancements, new challenges for diagnosis 
of HIV infection abound. HIV vaccine studies, increasing pre- 
exposure prophylaxis (PrEP) usage and PrEP breakthrough 
infections28–31, and very early initiation of HIV treatment have 
improved HIV prevention and care considerably, but require fur-
ther evaluation of the impact on key viral and immunological 
markers of HIV, upon which existing diagnostic assays rely30,32–37. 
Vaccine trial participants frequently have anti-HIV positive 
assay results, known as vaccine-induced seropositivity (VISP), 
despite being HIV-negative34, and very early use of anti-retroviral 
treatment (ART) (including with PrEP) can have the opposite 
effect, leading to non-reactive antibody or ambiguous assay 
result combinations38. This likely occurs as a result of inhibited 
antibody production due to lack of sustained antigenic stimula-
tion during a time when viral load is typically spiking39,40. Rapid 
reduction in viral load before antibody production is fully 
underway can lead to lower antibody titers and less time for 
antibodies to mature; assays may then detect antibodies later 
than expected, or not at all35. These types of new, increasingly 
important challenges contribute to potentially inaccurate diag-
noses at the individual level and misinterpretations of data 
on the global stage, including inaccurate national or regional 
prevalence and incidence estimates, and measurement error 
against the WHO care cascade indicators and UNAIDS 90-90-90 
targets. To reduce data misinterpretation, we require creative 
approaches to ongoing evaluation and enhancements of diag-
nostic assays and algorithms, necessitating access to suitable 
specimens for assay development and evaluation.
Specimen repositories previously built by the Centers for 
Disease Control and Prevention (CDC), National Institutes of 
Health (NIH), and others have supported many diagnostic devel-
opments to date. However, specimens in those repositories have 
often had limited distribution and no mechanism for regular 
replenishment, leading to a resistance of many major funders 
to allocate money toward sustaining those repositories or 
investing in additional specimen repository projects. Well- 
maintained repositories with substantial specimen distribution 
and replenishment will allow multiple current questions to be 
answered, and will enable us to anticipate and proactively address 
future challenges to the diagnosis, monitoring, and evaluation of 
HIV infection.
Review and findings
The Consortium for the Evaluation and Performance of HIV 
Incidence Assays (CEPHIA) was formed in 2011 with fund-
ing from the Bill and Melinda Gates Foundation; it was created 
in specific response to a need for cultivated specimens iden-
tified during an international Incidence Assay Critical Path 
Working Group, convened to review challenges and propose 
solutions to assay development for use in a surveillance and 
research context41. CEPHIA was created to support the devel-
opment of existing and new HIV incidence assays, improve 
data analysis and interpretation of incidence assay results, and 
bring consensus to the field. CEPHIA is strengthened by its 
wide membership (see Acknowledgements), including close 
work with the World Health Organization/UNAIDS Techni-
cal Working Group on HIV Incidence Measurement and Data 
Use42, and a large variety of researchers and funders across the 
globe (see Table 1 and Table 2). Importantly, the consortium 
was charged with setting standards and conducting independent 
evaluations of existing and new incidence assays, in order to 
remove real or perceived assay developer bias and allow direct, 
objective comparison of HIV incidence assays. To do this, one of 
CEPHIA’s primary aims was to establish a repository of samples 
suited for these purposes.
For this paper, we review the foundation and describe the evolv-
ing development of the CEPHIA repository from late 2011 
through March 2019, as a potential exemplar of a model for 
consolidated repository development. We calculate the esti-
mated value of the first stage of the CEPHIA investment 
(CEPHIA-1, January 2011 through December 2013) by review-
ing funding award documentation during that period, and 
summing the value of all research and programmatic uses of 
CEPHIA-1 samples between January 2012 and March 2019, then 
dividing by the total sum of the expenses related to establishment 
of the CEPHIA-1 repository, as well as maintenance and utiliza-
tion of the repository during the initial project period. We identify 
critical features of a high-value repository, for consideration in 
future efforts to develop such a resource, and identify new types 
of specimens that could be included in a consolidated repository.
Review of the CEPHIA Repository
As of March 2019, the CEPHIA repository included 94,654 
aliquots of different sample types, collected from 3,383 unique 
individuals with 13,856 different timepoints. Most of these 
specimens have well-estimated durations of infection at the 
time of collection, demographic information, and detailed 
clinical information about ART history, elite control, and other 
characteristics.
In addition to performing its own evaluations of 11 existing HIV 
incidence assays, since 2012 CEPHIA has distributed over 50 
purposely designed specimen panels to 19 different research and 
development groups. Unified data from extensively character-
ized, highly valuable specimens has allowed this resource to sup-
port biomarker discovery, assay optimization, and development 
Page 3 of 18
Gates Open Research 2019, 3:1511 Last updated: 30 AUG 2019
Table 2. CEPHIA value generation.
Item Expense Return
Costs of repository $1,590,978
Specimen acquisition $172,000
Specimen maintenance $396,091
Panel building and shipment $492,100
Database management $315,000
Oversight $215,787
Projects made possible because of repository
NIH awardees $4,383,760
Gates awardees $3,000,000
MeSH Consortium incidence applications $1,300,000
CEPHIA Assay Evaluations $1,807,223
TOTAL YIELD $10,490,983 / $1,590,978 = $6.59/$1 
Table 1. Examples of HIV assay development and related research studies supported by CEPHIA.
Study type Examples
Focused hypothesis-driven studies •   How the gut inflammasome and specific HIV antibody subclasses 
change as HIV infection evolves
•   How timing of treatment initiation after HIV infection impacts kinetics 
of HIV reservoir seeding and opportunity for cure
Non-hypothesis-driven efforts to identify 
novel signatures of recent HIV infection
•   Searches for antibodies reactive to peptoids in a large ‘peptoid 
shape library’
•   Multiplexed assay utilizing viral and antibody markers identified and 
interpreted through a machine learning algorithm
CDC and NIH funded projects •   Examination of the factors in HIV resistance, including mutation, 
selection, recombination, and drift
•   Development of a single genomic assay for HIV incidence and 
transmitted drug resistance mutation screening
•   Independent evaluation of the Sedia Asanté™ HIV-1 Rapid 
Recency® Assay, currently in use by PEPFAR at international sites
Theoretical and toolkit innovations •   Development of a theoretical framework and web-based tool for 
consistent time of infection estimation based on subject-level 
diagnostic testing histories and the properties of diagnostic assays
of new strategies for estimating duration of HIV infection 
by interpreting diagnostic histories, as shown in Table 1.
The initial CEPHIA repository was built not by collecting 
new specimens, but by incorporating historical specimens that 
otherwise would have been discarded due to lack of storage 
and maintenance resources. Bringing together smaller, more 
narrowly-defined repositories added value to specimens that 
may otherwise have been underutilized or even destroyed, 
and thus demonstrates the utility of a consolidated repository. 
However, CEPHIA faced many challenges in the development 
of its initial repository, as discussed in Box 1. Other groups 
attempting to build new consolidated repositories will likely face 
these challenges, making it necessary to determine the return 
on investment (ROI) required to justify funding for any new 
repository.
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Box 1. Challenges to developing and maintaining an 
effective specimen repository
Finding specimens
•   Location of specimens with sufficient provenance
•   Location of specimens with appropriate volumes
•    Methods for obtaining specimens: Collaborate, buy, 
and/or negotiate
•    Replenishment of the archive as specimens are utilized, 
while maintaining consistency across standard panels 
available to researchers and assay developers
Funding
•    Securing of funding for repository development, 
management and maintenance, including freezer, 
laboratory technician time to pull and aliquot requested 
specimens, and data management time
•    Demonstration of adequate return on investment, when 
the value created by disseminated panels is not always 
readily calculated
Ethics
•    Marriage of the different ethical requirements of the 
projects that collected specimens
•    Control of specimen usage when supported by 
commercial companies, who will later sell a product 
based on evaluations using specimens from the 
repository
Ownership and management
•   Creation of appropriate archive management structure
•    A priori decisions about the makeup of standard panels
•    Determination of who should receive valuable, 
irreplaceable specimens
•    Strategies to appropriately acknowledge the historical 
projects that collected these specimens
Data
•    Standardization of the results of evaluations between 
assays
•    Standardization of background data of specimens from 
many different sources
•    Dissemination of results in ways that best benefit the field
•    Creation and advertisement of tools to help people with 
their own analyses
While there are numerous benefits to the field, maintenance 
of a repository like CEPHIA is costly, and funding to sup-
port administrative and operational (i.e. non-research) tasks 
has been difficult to sustain. Specimens sitting in a freezer wait-
ing to be distributed through a panel are often seen as a drain 
on resources; yet they can also be seen as a potential supply of 
invaluable (and sometimes irreplaceable) material, such as in the 
case of specimens from ART-naïve individuals with longstanding 
infections, increasingly difficult to come by worldwide.
It is difficult to quantify the value gained from identifying 
poorly performing assays so they can be removed or limited in 
the market; improving the understanding, confidence and appli-
cation of well-performing assays; developing new research 
concepts and opportunities by adding value to previous studies; 
or supporting external quality assessment (EQA) programs. 
Repository value, however, can be measured in several ways, 
including scientific value (measured through grants awarded, 
papers published, patents filed, diagnostic improvements made 
and new assays developed, public health application of methods, 
and subsequent reduction in infections), regulatory acceptance 
(through use of the repository to allow FDA, CE, and WHO 
approval of assays), financial gains (through payments from 
manufacturers, value of grants awarded, royalties, reduction 
in ancillary health costs through reduction in burden of 
disease), and also from a reduction in resources spent on tech-
niques that have been shown to be ineffective. To date, our 
estimates of expense and funders’ investments into the original 
plasma-only CEPHIA Repository (also known as “CEPHIA 1”, 
funded by the Bill and Melinda Gates Foundation, OPP1017716) 
have had a strong value per dollar invested; when taking into 
account the value of projects made possible directly or indi-
rectly by CEPHIA 1, we estimate each dollar invested yielded 
approximately $6.59 in scientific advancement (see Table 2).
In addition to the financial yield, there were a number of other 
impacts of CEPHIA 1, including:
•    Standardization of HIV incidence assays, and rejection 
of tests that don’t work. CEPHIA was primarily initiated 
to conduct independent evaluations of assays in the glo-
bal market that were theoretically able to detect recency 
of HIV infection. These evaluations were completed on 
11 assays, with formal evaluations (also known as “blue 
books”) available at the following location: http://www.
incidence-estimation.org/page/cephia-assay-evaluations. 
In addition to these detailed evaluations there were a 
number of papers published by CEPHIA on the per-
formance and appropriate use of available assays43–45. 
These evaluations and related publications have allowed 
major international donors to confidently use appropri-
ate incidence assays in major surveillance activities and 
impact assessments, such as the Population HIV Impact 
Assessments (PHIAs) currently being conducted in 14 
PEPFAR-supported countries46.
•    Innovative research to advance the field. There have 
been 21 separate large-scale research projects funded by 
NIH, the Bill and Melinda Gates Foundation, and oth-
ers, using CEPHIA specimens as a foundation for inves-
tigation of assays in various HIV incidence and diagnos-
tic applications. Eleven scientific articles2,11,26,27,43,45,47–51 
highlighting important findings about the use (and 
misuse) of HIV incidence assays have been published 
to date with CEPHIA authorship, as a direct result of 
CEPHIA specimens being made available to researchers 
upon request.
•    Influence on guidance and standards set by the World 
Health Organization and UNAIDS. Through participa-
tion on the WHO/UNAIDS Technical Working Group 
on HIV Incidence Measurement and Data Use, CEPHIA 
has had direct and ongoing influence over the information 
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discussed at Technical Working Group meetings and sub-
sequently shared through various guidance documents 
and technical updates, available at https://www.who.
int/hiv/pub/surveillance/en/; as one example, this influ-
ence led to a 2015 Technical Update recommending 
that incidence assays always be used in conjunction with 
viral load to appropriately calculate incidence at the 
population level52.
•    Research informed by CEPHIA analyses and les-
sons learned. In addition to specific publications, many 
areas of research and development have been largely 
informed by CEPHIA’s work, including HIV cure 
research, antibody profiling, and infection dating. As one 
concrete example, to support analyses within CEPHIA it 
was critical to standardize estimated times since infec-
tion for each specimen timepoint. This was originally 
done using the conventionally-understood Fiebig staging 
method53. However, this was quickly found to be limiting 
as many specimens came from people who entered the 
source cohort after reaching Fiebig stage V, when anti-
bodies had matured and the acute infection period had 
passed, yielding little-to-no information about infection 
timing. To address this limitation, CEPHIA devel-
oped a new method of infection dating now gaining 
traction26,27; the major benefit of the EDDI method is that 
it allows for a point estimate and associated credibility 
interval for date of first detectable infection of any per-
son who has at least one positive and one prior negative 
HIV test of any kind. With the EDDI method, the tests 
do not have to be run on the same day and do not have 
to be run during the acute phase of infection in order to 
generate an estimated date on which a viral load assay 
with a 1 copy/mL limit of detection would have a 50% 
chance of detecting the infection (date of first “detect-
able infection”). The EDDI method is flexible and a 
major advance over the Fiebig method given the latter’s 
increasing limitations in this new era of HIV assays.
Critical features of a high-value repository
We identified the following as critical features of a high-value 
repository: 1) extensively-characterized HIV-positive samples, 
including serial specimens from people with acute infection, 
seroconverters, and treated subjects, enabling diagnostic, 
pathogenesis, cure, and co-morbidity studies, 2) high-quality 
clinical background data, 3) multiple collaborations facilitating 
ongoing specimen collection and replenishment, and 4) sustained 
records of high-level utilization and specimen turnover, with 
thousands of samples shared annually. In Figure 1, we describe the 
features of a large consolidated repository that meets these “high-
value” criteria on a broad scale with centralized management.
Given the changing context of HIV diagnostics in 2019, we 
identified the need for new types of specimens that should be 
available through a consolidated repository. In order to suffi-
ciently support the development of assays that will meet today’s 
diagnostic challenges, we need a repository with the infrastruc-
ture to support rapid receipt, management, and dissemination 
of panels with the following types of specimens:
1.    Large-volume, extensively-characterized HIV-positive 
samples, including serial specimens from seroconverters 
and patients with particularly early ART initiation;
2.    Baseline samples from individuals starting PrEP and 
serial samples collected while on and after stopping 
PrEP, including from documented and potential PrEP- 
breakthrough infections;
Figure 1. Consolidated repository concept.
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3.    Chronic viremics (i.e. not virally suppressed even 
with longstanding infection)
4.    Elite controllers (i.e. continuously virally suppressed 
despite not having been treated)
All specimens must have high-quality clinical background data 
on the patients, to ensure their utility for diagnostic, pathogenesis, 
cure, and co-morbidity studies. This will require multiple 
collaborations to facilitate specimen collection and replenish-
ment; this is no small task considering the legal, ethical, and 
logistical implications of sharing large-volume specimens across 
the globe, for reasons other than their original intention. An 
effective repository should have thousands of samples shared 
annually, requiring extensive data management to track ship-
ments, specimen usage, panel outputs, and high-level specimen 
turnover and replacement. A repository system with the capac-
ity to independently evaluate assays that have performed well 
on blinded panels run in developers’ laboratories (as CEPHIA 
has) also requires collaboration with advanced statisticians who 
can perform high-quality data analysis and routinely share infor-
mation; our experience has shown that simply disseminating 
evaluation results is not sufficient, and hands-on technical assist-
ance strategies are required in order to support clinicians and 
researchers in understanding what the results really mean.
Discussion
Despite having a reputation as expensive white elephants, our 
review highlights that specimen repositories can play an invalu-
able role in the development, optimization, and validation of 
diagnostic assays. The CEPHIA repository demonstrates how a 
targeted approach can identify and capture a wealth of specimens 
and associated information that already exists, and gain value 
by being drawn together for a different purpose. Developing the 
archive required overcoming a number of significant challenges, 
and despite its demonstrated value given the financial invest-
ment, lack of consistent funding threatens the existence of the 
CEPHIA repository and the collaborative team that supports 
its use. To successfully develop and sustain a consolidated 
repository model, we must think in new ways about our 
scientific work as part of a collective whole. To this end, through 
this review we have identified critical features of a high-value 
repository, leading to the following proposals:
1.    Funders of studies should be more explicit in their 
guidance to awardees about requirements to release 
specimens utilized for the study as soon as any 
primary or secondary aims of the initial study 
are complete, and this should be completed within a 
defined timeframe. ‘Ownership’ of specimens collected 
through studies is a significant hurdle to overcome in the 
development of a consolidated repository. Under-
standably, individuals typically do not want to release 
specimens held in their archives without guarantees 
that the work performed on them is going to be valu-
able, and institutions worry about yielding control of 
specimens under their purview. Indeed, specimens in a 
consolidated repository may be used in ways that diverge 
from the expertise of the researchers who were instru-
mental in their collection, often leading to further reluc-
tance to collaborate. Funders should also look across the 
repertoire of studies they fund, to help identify where 
specimens may be available and how specimens collected 
from one study may be beneficial to others.
2.    In developing ethical approval for studies, more 
emphasis should be placed on ensuring that speci-
mens collected can be used for other, perhaps currently 
unknown, purposes. This may mean setting a period of 
time for the study after which anonymization of specimens 
is routinely conducted so they may be broadly shared. 
It will also likely require that further explanation of 
the potential uses of specimens be given to study 
participants at the time of consent.
3.    Journals should come to some general consensus about 
the best mechanisms for acknowledging research-
ers who contributed specimens that were later used 
for a secondary study. In a large repository with rapid 
turnover of specimens, inclusion of all researchers 
contributing specimens into the authorship list of any 
subsequent papers is likely impractical. Yet especially 
in academia, where a publication record is typically a 
major factor in continued employment and promotion, 
rights to authorship is critical currency when determin-
ing whether specimens should be shared with a reposi-
tory system for future use. Recognition of the hard 
work that went into specimen acquisition and initial 
maintenance – as well as incentivization for collegial rela-
tionships between researchers – would be an important 
way to ensure successful construction of a consolidated 
repository.
4.    Major funders should ensure that studies col-
lect as much ancillary data around the work they 
do as possible without infringing on the rights of 
study participants. While most researchers work to 
minimize and streamline data collection to improve 
participant enrollment rates (i.e. not requiring partici-
pants to disclose full medical histories), there are many 
simple factors of study protocol or process that could 
help with the effective use of specimens for subse-
quent analyses. One clear example of this is the type of 
assay used to confirm an infection, which due to differ-
ent sensitivities and specificities may, over time, affect 
how an assay result may be interpreted or how a specimen 
may be categorized.
5.    Leadership of a consolidated repository should be 
supported by the endorsement of major funders and 
normative agencies. With international, influential 
commitments to the development and use of a major 
repository to address upcoming challenges to HIV 
diagnostics, the ease of securing appropriate specimens 
will dramatically increase. The repository should be 
open internationally, with its use based on scientific 
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need, with clear systems and guidelines for specimen 
access. Further, management of the repository should not 
just include physically obtaining, storing, and shipping 
specimens, but should also involve skilled support for 
data analysis, to help guide users in proper application 
of the specimens and their associated information. 
Standards should be set for commercial use of speci-
mens, such that for-profit development is allowed with an 
appropriate exchange of funding that helps the repository 
be sustained for the future.
6.    Repository owners should attempt to develop an ROI 
methodology. To assist with sustainable funding for 
useful consolidated repositories, a mechanism to fairly 
track investments, expenses, and returns is imperative. 
Such a system will help potential funders see the ben-
efits of their investments in these projects, and should 
also include metrics to determine whether a repository 
should continue or whether the ROI has fallen to a 
point such that future funding should cease and speci-
mens should be disseminated for storage in other more 
productive settings.
In summary, with strong governance and leadership, a con-
solidated repository provides academic investigators and com-
mercial assay developers with easy access to diverse specimens 
through a large consolidated archive of specimens from multi-
ple studies, helping to advance improvements to HIV diagnos-
tic assays and ultimately elimination of HIV. An international 
commitment to the development and/or maintenance of this 
type of resource is imperative, for the field of HIV diagnostics 
and incidence measurement to continue to move forward and face 
new challenges.
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